Advances in COVID-19 and Cancer
Since the end of 2019, physicians all over the world have faced the challenge of understanding a new and complex disease: COVID-19. Initially, COVID-19 was believed to be a primarily respiratory disease; however, it quickly emerged that the immune system was also involved. Inflammation was identified as a primary player in the pathogenesis of the various manifestations of this disease, and it also appears to play a role in more long-term consequences of infection, even in terms of inflammatory disorders. Another interesting aspect is the role of COVID-19 in patients who already presented with inflammatory disorders or immune disorders, many of whom experienced post-infective reacutizations.
People with cancer represent a large group of patients with immune alterations, either as a result of the tumor itself or the therapies the patient must undergo.
Articles for this Topic are required to assess the role of COVID-19 in cancer, both in its pathogenesis and its progression. Authors may also focus on the role of cancer in promoting COVID-19 infections, as well as its peculiar manifestations in this group of patients.
Dr. Laura Franza
Dr. Rossella Cianci
|First Decision (median)
Journal of Clinical Medicine
Tropical Medicine and Infectious Disease
Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.
MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:
- Immediately share your ideas ahead of publication and establish your research priority;
- Protect your idea from being stolen with this time-stamped preprint article;
- Enhance the exposure and impact of your research;
- Receive feedback from your peers in advance;
- Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.